GTx to Present Results on Enobosarm 9mg in Women with Metastatic Breast Cancer at 2014 San Antonio Breast Cancer Symposium

GTx, Inc. (NASDAQ: GTXI) today announced that the results from its positive proof of concept Phase 2 clinical trial evaluating enobosarm 9mg in post-menopausal women with estrogen receptor (ER) positive and androgen receptor (AR) positive metastatic breast cancer will be featured in a poster presentation at the San Antonio Breast Cancer Symposium taking place December 9 - 13, 2014, in San Antonio, Texas.

Results from a 22 patient, open-label Phase 2 clinical trial evaluating an oral daily dose of 9mg of enobosarm for the treatment of ER positive and AR positive metastatic breast cancer in women who have previously responded to hormonal therapy for the treatment of their advanced breast cancer, will be presented at a poster session as follows:

Copies of the poster will be available by contacting the Company.

The Company and clinical experts will host an Investor Meeting on Thursday, December 11, 2014 at 7:30 p.m. CT to review the Company’s breast cancer program as well as the Phase 2 results. The meeting will take place in the River Walk Room at the Mokara Hotel & Spa. A live webcast and replay of the presentation will be available on the investor section of the GTx website at www.gtxinc.com.

About GTx

GTx, Inc., headquartered in Memphis, Tenn., is a biopharmaceutical company dedicated to the discovery, development, and commercialization of small molecules for the treatment of cancer, including treatments for breast and prostate cancer, cancer supportive care, including prevention and treatment of cancer-related muscle wasting, and other serious medical conditions.

Forward-Looking Information is Subject to Risk and Uncertainty

This press release contains forward-looking statements based upon GTx's current expectations. Forward-looking statements involve risks and uncertainties, and include, but are not limited to, statements relating to GTx's future development of enobosarm and the potential value thereof. GTx's actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, without limitation, the risks (i) that GTx’s two planned Phase 2 clinical trials of enobosarm in patients with AR positive advanced breast cancer may not be initiated or completed on schedule, or at all, or may otherwise be suspended or terminated; (ii) that the development of enobosarm for the treatment of patients with AR positive advanced breast cancer is at an early stage and is subject to the significant risk of failure inherent in the development of early-stage product candidates; (iii) that GTx may not be able to obtain required regulatory approvals to advance the development of or commercialize enobosarm in a timely manner or at all; and (iv) that GTx will continue to need additional funding and may be unable to raise capital when needed, which would force GTx to delay, reduce or eliminate its enobosarm development program. GTx’s actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties. You should not place undue reliance on these forward-looking statements, which apply only as of the date of this press release. GTx’s quarterly report on Form 10-Q for the quarter ended September 30, 2014 contains under the heading “Risk Factors” a more comprehensive description of these and other risks to which GTx is subject. GTx expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in its expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based.